Professor David Lalloo

Director Liverpool School of Tropical Medicine and Professor of Tropical Medicine

Having undergone initial training in Newcastle upon Tyne, David Lalloo trained in General (Internal) Medicine, Infectious Diseases and Tropical Medicine, spending three years in Papua New Guinea. He undertook clinical and laboratory research in Oxford before moving as Senior Lecturer to the Liverpool School of Tropical Medicine in 1999. 

Since then he has focused on clinical trials in the tropics, particularly in HIV related infections, malaria and envenoming. He currently has collaborations and studies in a number of countries including Malawi, Uganda, Sri Lanka, Vietnam, Kenya, Nigeria, eSwatini (formerly known as Swaziland) and South Africa. He has worked with the MLW Programme in Malawi for almost twenty years. He holds an appointment as an Honorary Consultant at the Royal Liverpool University Hospital and remains clinically active.  

Professor David Lalloo is LSTM's Director and is Chair of the Wellcome Trust/MRC/DfID/DH Global Clinical Trials Panel. Prior to taking up the Directorship of LSTM in January 2019, David was Dean of Clinical Sciences and International Public Health and was Director of the Wellcome Trust Liverpool Glasgow Centre for Global Health Research and the Liverpool Wellcome Trust Clinical PhD Programme.

Research 

Current projects include trials of treatment in cryptococcal disease, understanding causes of fever in Malawi and estimating burden of snakebite in South Asia. Previous work has been published in major journals including PLOS Medicine, Lancet Infectious Diseases and the NEJM and trials have informed international clinical guidelines relevant to care in the tropics and the UK.

Other relevant expertise, professional memberships

  • Chair: Public Health England Advisory Committee on Malaria Prevention in Travellers (2010-2018)
  • Chair: Wellcome Trust/MRC/DfID/DH Global Clinical Trials Panel
  • Chair: NIHR Independent Scientific Advisory Group for DHSC Global Health Research Programme
  • Member: MRC Global Health Group
  • Member: Wellcome Trust Interview Panel (2015-2018)
  • Chairman of a number of international Trial Steering and Data Monitoring Committees
  • Member: CMO Scientific Advisory Group on Zika (2016)
  • Member: CMO Scientific Advisory Group on Emergencies (SAGE) for Ebola (2014-5)
  • Member: WHO Advanced HIV Guidelines Group
  • Member: Public Health England Expert Advisory Group on Anti-venoms,
  • National Poisons Service Advisor on Envenoming
  • Member; UK JCVI Travel Sub-group
  • Deputy Editor: PLOS NTD

Current grants/projects

Project Title

Role

Awarding Body

Amount

Grant period

NIHR Global Health Research Group on Sepsis

Co-applicant

NIHR

£2,000,000

2018-2021

Drivers of AMR Resistance in Uganda and Malawi

Co-applicant

MRC

£3,046,154

2018-2021

Severe Malaria Africa – A consortium for Research and Trials

Co-applicant

Wellcome Trust

£4,028,000

2018-2022

MLW Programme Core Award

Co-applicant

Wellcome Trust

£24.8 million

2018-2021

NIHR Group on African Snakebite Research

Co-applicant

NIHR

£2,000,000

2017-2018

Health in a changing climate: snake bite in South Asia

Principal Applicant

MRC

£512,000

2017-2018

High Dose AMBISOME Cryptococcal Meningitis in SSA

Co-applicant

EDCTP

£8,500,000

2017-2020

Health priorities in resource-limited settings- Wellcome Trust Clinical PhD Programme

Principal Applicant

Wellcome Trust

£7,587,000

2017-2022

Fracture Union in HIV positive patients

PhD fellowship

Wellcome Trust

£400,000

2016-2019

Improving the impact of existing Malaria Products - ACTs

Co-applicant

EDCTP

£400,000

2015-2017

Centre of Research Excellence Translational Venom and Antivenom Research.

Co-Chief

Investigator

National Health and Medical Research Council – Australia

£1,533,000

 

2015-2019

Characterising  MTB isolates and host whole blood transcriptome in HIV-TB co-infected patients

PhD fellowship

Wellcome Trust

£374,487

 

2015-2018

Wellcome Trust Liverpool-Glasgow Centre for Global Health Research

Principal applicant

Wellcome Trust

£760,000

2013-2018

A multi-centre randomized placebo controlled trial of dexamethasone to improve the outcome of cryptococcal meningitis

Co-applicant

MRC/DfID/Wellcome Trust

£4,593,228

2012-2016

Programmatic implementation of ACTs in Malawi

Principal Applicant

Gates Foundation

£1,732,000

2008-2016

Pharmacovigilance of ACT

Principal Applicant

Gates Foundation

£600,516

2009-2016
Recent publications: 

    Selected publications

    • Molloy SF, Kanyama C, Heyderman RS et  (Lalloo DG 33rd/36 authors). Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018 Mar 15;378(11):1004-1017..doi: 10.1056/NEJMoa1710922. PubMed PMID: 29539274

      Beardsley J, Wolbers M, Kibengo FM et al,  (Lalloo DG 30th of 31 authors); CryptoDex Investigators. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016 Feb 11;374(6):542-54. doi: 10.1056/NEJMoa1509024.

      MacPherson P, Lalloo DG, Webb EL et al. , Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):372-9. doi: 10.1001/jama.2014.6493

      Day JN, Chau TT, Wolbers M et al. (Lalloo DG joint senior author). Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013 Apr 4;368(14):1291-302. doi: 10.1056/NEJMoa1110404

      Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A , Kenya Mugisha N,  Grosskurth H , Kamali A, Lalloo DG.  Primary prophylaxis of cryptococcal disease using fluconazole in HIV positive Ugandan adults - a double blind, randomised, placebo controlled trial. Lancet Infectious Diseases. 2011 Dec;11(12):933-41.

      Ajdukiewicz KM, Cartwright KE, Scarborough M, Mwambene JB, Goodson P, Molyneux ME, Zijlstra EE, French N, Whitty CJ, Lalloo DG. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial (link is external). Lancet Infectious Diseases. 2011 Apr;11(4):293-300

      De Silva HA,  Pathmeswaran A,  Jayamanne S,  Samarakone SMSB,  Hittharage A, Kalupahana R,  Ratnathilake A, Uluwatte W, Ranasinha CD, Aronson JK, Armitage J, Lalloo DG, De Silva HJ. Promethazine, hydrocortisone, and low-dose adrenaline (alone and in combination) in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double blind, placebo-controlled trial. PLOS Medicine. 2011 May; 8(5):e1000435

      Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008 Nov 4;5 (11):e218. doi:10.1371/journal.pmed.0050218.

      Scarborough M, Gordon SB, Whitty CJM, French N, Njalale Y, Chitani A, Peto TEA, Lalloo DG,  Zijlstra EE. Steroids for bacterial meningitis in adults with HIV in sub-Saharan Africa. New England Journal of Medicine. 2007: 357:2441-50

      Lalloo DG, Olukoya P, Olliaro P. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis. 2006 (12):780-93.

      Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N; International Artemesinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363: 9–17

      De Silva HA, Fonseka M, Pathmeswaran A, Alahakone D, Ratnatilake GA, Gunatilake SB, Ranasinha CD, Lalloo DG, Aronson JK, de Silva HJ.  Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial.  Lancet. 2003 Jun 7;361(9373):1935-1938

      Fekade D, Knox K, Hussein K, Lalloo DG, Coxon RE, Warrell DA. Randomised double-blind placebo controlled study of ovine polyclonal anti- tumour necrosis factor _ FAb antibodies in the Jarisch Herxheimer reaction of louse-borne relapsing fever: a human model of septic shock. New Eng J Med. 1996 Aug 1;335(5):311-5